Description: Novo is positioning itself as a long‑term leader across multiple obesity segments.

Description: Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel targets.

Description: Now set to collaborate with Eli Lilly to develop drugs in the AI era, Nvidia looks to trigger a new climb.

Description: Strive Compounding Pharmacy, one of the nation's most celebrated providers of compounded medications, has filed a federal antitrust lawsuit against pharmaceutical giants Eli Lilly and Novo Nordisk, alleging a coordinated effort to suppress competition and limit patient access to lawful compounded GLP-1 medications.

Description: Retatrutide is an exciting GLP-1 drug that has explosive potential.

Description: Novo Nordisk (NVO) will keep looking for deals to expand its obesity portfolio, CEO Mike Doustdar sa

Description: The company is benefiting mightily from its portfolio of weight-loss drugs.

Description: In recent days, Revvity, Inc. updated its outlook for the fourth quarter and full year 2025, guiding to approximately US$772,000,000 in Q4 revenue and about US$2.86 billion for the year, while indicating adjusted earnings per share should exceed its prior guidance range. A separate announcement revealed that Revvity and Eli Lilly are jointly expanding access to Lilly’s TuneLab AI models through Revvity’s Signals platform, underscoring Revvity’s push to embed advanced AI and federated...

Description: Plenty of growth lies ahead for these top healthcare companies.

Description: Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Eli Lilly Canada Inc. ("Lilly") announced today that Ontario leads the way as the first province to add Olumiant® for severe alopecia areata to its public drug formulary—the first and only treatment for adult patients with severe alopecia areata available through public coverage.

Description: What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?

Description: Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Description: Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.”

Description: The GLP-1 giants are the first to try out this new model, but more companies may follow.

Description: Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and

Description: Eli Lilly (LLY) says its weight-loss pill is on track to be approved in the US, lagging behind Novo Nordisk (NVO). Eli Lilly CFO and executive vice president Lucas Montarce sits down with Market Catalysts host Julie Hyman to outline the company's expectations for its weight-loss pill and its anticipated impact on market penetration. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Investing.com -- Novo Nordisk CEO Mike Doustdar said the company faces headwinds in its international operations in 2026 as competition increases following the loss of market exclusivity in several countries.

Description: Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S

Description: Eli Lilly (LLY) is teaming up with Nvidia (NVDA) to invest in an artificial intelligence (AI) innovation lab. Eli Lilly CFO and executive vice president Lucas Montarce joins Market Catalysts host Julie Hyman to discuss how the pharmaceutical company is leveraging AI to expedite drug discovery. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: The Dow Jones Industrial Average was down, the S&P 500 was roughly flat and the Nasdaq Composite was

Description: Dow Jones retail giant Amazon is approaching a fresh buy point, as the stock market holds near record highs.

Description: Both companies now aim to win in the oral weight loss drug market.

Description: Microsoft headlines Zacks' Analyst Blog as strong cloud, AI, and semiconductor trends shape outlooks across tech and healthcare.

Description: NVO jumps nearly 19% in a month primarily on the FDA approval and launch of oral Wegovy, the first GLP-1 pill for obesity and cardiovascular risk reduction.

Description: Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.

Description: Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer discussed, along with recent market rotation. When a caller asked about the stock, here’s what Cramer had to say in response: “Okay, no, look, I’m a Eli Lilly guy, okay? I’m going to stick with it. If I’m going to do Viking, I’m going […]

Description: The gap may be too hard to close in the next 12 months.

Description: Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

Description: We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]

Description: Nvidia Pushes Deeper Into Health Care With Major Eli Lilly Partnership

Description: AbbVie has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs. The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development. AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.

Description: Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

Description: SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ​Viagra in 1998, CEO Albert Bourla said on Monday. Bourla said that even when the drugmaker was ‌negotiating its purchase of weight-loss drugmaker Metsera, initially announced in September 2025, Pfizer did not expect the cash-pay market for obesity drugs ‌currently dominated by Eli Lilly and Co and Novo Nordisk to get s

Description: Eli Lilly (LLY) concluded the recent trading session at $1, signifying a +1.64% move from its prior day's close.

Description: The National Retail Federation (NRF) is hosting its Retail's Big Show conference in New York City this week. Attending the event, Yahoo Finance Senior Reporter Brooke DiPalma sat down with KPMG US consumer & retail sector leader Duleep Rodrigo and PwC partner and US consumer markets industry leader Alison Furman to hear how retailers will be employing AI applications and how companies are expected to adjust to the adoption of GLP-1 weight-loss drugs and more active lifestyles by consumers. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend.

Description: Find insight on Pfizer, Johnson & Johnson and more in the latest Market Talks covering the health care sector.

Description: Nvidia announced AI partnerships with two biotech firms to transform the way lifesaving drugs are discovered and manufactured.

Description: Nvidia stock was languishing Monday despite news of a partnership with pharmaceutical company Eli Lilly The chip company’s investors remain focused progress on sales in China and the health of the wider artificial-intelligence sector. The stock is down 1.8% over the past month, as a flurry of robotics and autonomous-driving related announcements at the CES trade show, formerly known as the Consumer Electronics Show, failed to provide a boost. Nvidia said Monday that it was joining with Eli Lilly to fund an AI lab with an investment of up to $1 billion over five years to build models for biology and chemistry.

Description: BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly.

Description: Microsoft beat software peers as Azure's 25% cloud share and OpenAI-led AI lift cash flow, despite competition, regulation and rising AI capex.

Description: Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that it entered into partnership agreements with 23 companies in 2025. In addition, Adimab achieved 50 technical and development milestones across numerous collaborations.

Description: A new co-innovation lab in the San Francisco Bay area will see Lilly and NVIDIA scientists work alongside each other to fuel drug discovery improvements.

Description: Eli Lilly’s presence in France has spanned more than six decades, but rumors of an acquisition suggest the pharmaceutical giant could be looking to expand its footprint in the country. French outlet La Lettre reported Monday that biotechnology company Abivax had become the subject of takeover interest by Lilly, which was prepared to offer 15 billion euros, or roughly $17.5 billion, to acquire it. Eli Lilly has yet to support a formal bid to Abivax’s board as it awaits clarity from French regulators on whether a bid would be subject to France’s foreign investment rules, the outlet reported.

Description: Yahoo Finance Senior Reporter Brooke DiPalma tracks Monday's top moving stocks and biggest market stories in this Market Minute. Taiwan Semiconductor Manufacturing Company (TSM) stock is moving higher on a New York Times report that the Trump administration is close to reaching a trade agreement with Taiwan. Nvidia (NVDA) and Eli Lilly (LLY) are partnering on drug discovery, jointly investing $1 billion to create a lab in San Francisco. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: Contract value passes $1.1 billion milestone

Description: One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive amounts of data far faster than humans, identifying potential drug candidates and predicting their effects. This could cut years off the traditional process, which often takes over a decade and costs billions. Eli Lilly ... Eli Lilly and Nvidia Make $1 Billion AI Bet to Revolutionize Pharma’s Future

Description: Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors.

Description: Monday is the first day of J.P. Morgan’s annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year. There is ample precedent: Last year, Johnson & Johnson announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering. The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.

Description: Nvidia and Eli Lilly are set to launch an AI lab in San Francisco.

Description: Abivax’s lead asset is obefazimod, an anti-inflammatory drug that has produced positive Phase III results.

Description: REDWOOD CITY, Calif., January 12, 2026--Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, today announced its $33.5 million Series B. The round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray.

Description: On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related condition. Psoriatic arthritis is linked to psoriasis (a condition that affects skin and nails). It causes joint pain, stiffness, and a skin rash. At 36 weeks, treatment with conc

Description: CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc

Description: It has strong momentum thanks to its current portfolio and several catalysts on the horizon.

Description: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Description: ABIVAX Société Anonyme (NASDAQ:ABVX) is among the 20 Best Performing Stocks in 2025. According to a story in the French-language newspaper La Tribune on December 24, 2025, there have been rumors that Eli Lilly has been drawing interest in the French biotechnology business ABIVAX Société Anonyme (NASDAQ:ABVX), TheFly reported. Its shares surged after the release, […]

Description: Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive agreement to acquire Ventyx Biosciences, Inc., which is a clinical-stage biopharmaceutical company that develops innovative oral therapies for patients with inflammatory-mediated diseases. Ventyx Biosciences, Inc. […]

Description: Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses. Lilly rode explosive GLP-1 drug demand to 53.9% revenue growth. Johnson & Johnson leaned on diversification across medical devices, pharmaceuticals, and consumer health to post 6.8% growth. GLP-1 Momentum Versus Diversified ... The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady

Description: Healthcare investing offers defensive characteristics during market turbulence, yet regulatory uncertainty and political risk can trigger sudden selloffs. For investors seeking pure healthcare exposure without picking individual stocks, Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) provides a low-cost entry point to this complex sector. What FHLC Delivers: Sector Exposure With a Concentration Problem FHLC tracks ... Is Fidelity’s Health Care ETF A Good Buy Right Now?

Description: Here's how we employ swing trading strategies of selling into strength, selling into weakness and cutting a loss quickly.

Description: While AI stocks Google, Broadcom and Palantir remain in demand, the best mutual funds shoveled massive sums into 3 stocks.

Description: Highly rated Eli Lilly stock is this week's Big Cap 20 pick to watch as it attempts to take out a flat-base buy point.

Description: These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.

Description: Shares traded at $22.91 after pricing at $18, valuing the clinical-stage biotech at about $1.2 billion.

Description: LOS ANGELES & BOSTON, January 09, 2026--Vida Ventures ("Vida"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co

Description: The Dow Jones, S&P 500 and Russell 2000 all hit highs on the stock market this week. Nvidia and AMD fell despite unveiling new AI chips at CES.

Description: After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.

Description: NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.

Description: Eli Lilly and Company (NYSE:LLY) is one of the Best Unstoppable Growth Stocks to Buy Right Now. On January 7, Michael Yee from UBS initiated coverage of Eli Lilly and Company (NYSE:LLY) with a Buy rating and raised the price target from $1,080 to $1,250. The analyst noted the company’s leadership in the obesity treatment […]

Description: JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Description: Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.

Description: Customers with commercial insurance will pay a minimum of $25 for a one-month supply, while the cost for those without insurance starts at $149 a month.

Description: SAN FRANCISCO, January 09, 2026--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.

Description: WALTHAM, Mass., January 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.

Description: ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.

Description: By Sneha S K Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.

Description: NEW YORK, January 09, 2026--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows.

Description: Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.

Description: Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand accelerates worldwide.

Description: With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.

Description: Eli Lilly's plan to buy Ventyx for $1.2 billion benefits more than the takeover target, an analyst said Thursday.

Description: NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U. pricing last year under pressure from President Donald Trump.

Description: Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one weight-related condition. At 36 weeks, treatment with concomitant Taltz and Zepbound met the primary and all key secondary endpoints for superiority to Taltz monotherapy. TOGE

Description: Novo Nordisk is trying to get back on track in the U.S., but it just lost an important worker in Washington. An internal memo said that Jennifer Duck, who was in charge of U.S. public affairs for Novo Nordisk, left the business on Jan. 5, Reuters reported. The developer of Wegovy and Ozempic is ...

Description: Walmart launched Better Care Services, a digital network of healthcare providers, and will trim prices on some wellness-related products.

Description: Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.

Description: Revolution Medicines shares jump nearly 29% to a record high after a WSJ report said AbbVie showed takeover interest, a claim the pharma giant later denied.

Description: ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth-quarter 2025 investor letter. The investment philosophy of the strategy is to invest in leading companies that are undervalued by the market in terms of their future growth potential. A copy of the letter can be downloaded here. Large-cap stocks continued their […]

Description: The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration. After peaking in February 2021, shares of Investor's Business Daily's Medical-Biomed/Biotech industry group plummeted more than 64% through April 2025.

Description: Benchling, the platform for scientific progress, today announced a strategic collaboration with Lilly TuneLab, an artificial intelligence and machine learning (AI/ML) platform created by Eli Lilly and Company (Lilly) to provide access to models trained on decades of Lilly's proprietary research data, representing over $1 billion in research investment. Through this program, Lilly is extending TuneLab's reach to Benchling's customer base of more than 1,300 biotech companies. Scientists will be ab

Description: Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to st

Description: Futures fell. Lockheed Martin and other defense giants jumped on Trump's proposed $1.5 trillion "Dream Military" budget.

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer offered insights on. Cramer highlighted the company’s latest spin-off plans for one of its divisions, as he commented: “The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. […]

Description: The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Description: Sources say Lilly is discussing a $14-a-share cash deal for Ventyx, potentially announced as soon as Wednesday.

Description: US firms are also staring down a multi-billion dollar patent cliff of their own, prompting a yearslong buying spree.

Description: MU, LLY and SKIL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 8th, 2026.

Description: The S&P 500 and Dow reversed from highs Wednesday, while the Nasdaq pared gains. Eli Lilly and Google flashed buy signals.

Description: Eli Lilly confirmed its $1.2 billion plan late Wednesday to acquire Ventyx Biosciences. Ventyx stock ran up nearly 40% during regular trades.

Description: By Puyaan Singh Jan 7 (Reuters) - Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, marking the Zepbound maker's latest push to

Description: Eli Lilly is Wednesday's IBD Stock Of The Day. Shares are breaking above a pair of bases as rumors swirl about a potential Ventyx buyout.

Description: The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Description: Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx.

Description: Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th

Description: SEATTLE & CAMBRIDGE, Mass., January 07, 2026--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced a global strategic collaboration and licensing agreement, and equity investment, with Eli Lilly and Company ("Lilly") to discover novel oncology treatments using InduPro’s proximity-guided platform.

Description: The market offers explosive potential as biology transitions to factory-scale production. Anchored by the USD 100 genome and high-margin consumables, the sector promises sustained scalability. Massive infrastructure investments, like Eli Lilly’s USD 4.5 billion campus, confirm a lucrative, long-term trajectory.Chicago, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The global biotechnology instruments market size stood at USD 92.12 billion in 2025 and is expected to reach USD 141.70 billion by 2035 with a 4.

Description: Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.3% in the morning session after the company announced a partnership to develop a new oral obesity drug and was reported to be in advanced talks to acquire Ventyx Biosciences for over $1 billion.

Description: Eli Lilly is in advanced talks to acquire Ventyx Biosciences for around $1 billion, according to people familiar with the matter. A deal for Ventyx, which specializes in developing pills that can treat inflammatory diseases, could come as soon as Wednesday, the people said. Ventyx, of San Diego, had a market value of a little over $500 million as of Tuesday afternoon.

Description: US equity futures were flat ahead of Wednesday's opening bell as traders digested labor market data.

Description: Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83% decline. This reflects a slightly less negative view of future sales potential tied to upcoming clinical data and Alopecia Areata optionality. Behind that small shift is a tug of war in Street research between bullish views that Rezpeg’s clinical profile could support higher long term revenue...

Description: SAN MATEO, Calif., January 07, 2026--BigHat Biosciences, a protein therapeutics company that combines state-of-the-art AI models with a high-speed automated wet lab, today announced a collaboration with Eli Lilly and Company (Lilly) focused on advancing machine-learning-enabled biologics discovery through Lilly TuneLab. This project expands BigHat’s relationship with Lilly, which includes a previously disclosed collaboration focused on the discovery and engineering of next-generation antibody th

Description: SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., president and chief executive officer of Recludix, will present an overview of the company’s progress at the Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company’s presentation will be on Thursday, January 15, 2026, at 9:30 a.m. Pacific Time. A

Description: Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

Description: Arrowhead’s stock rose 6% on market open after the announcement though continued to rise throughout the day.

Description: Biotech acquisition would expand Lilly's pipeline in inflammatory and metabolic diseases

Description: If you are wondering whether Eli Lilly's share price still makes sense after a long run up, or if the stock is starting to look stretched, this article walks through what the current market price could be implying about value. The stock most recently closed at US$1,064.04, with a 1.5% decline over the last 7 days, a 5.3% gain over the last 30 days, a 1.5% decline year to date, a 38.6% return over 1 year and a very large 5-year return that is well above 7x. Recent coverage of Eli Lilly has...

Description: Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG, with participation from new investors Longwood Fund, Asahi Kasei Pharma Ventures, Alexandria Real Estate Trust (ARE), and existing Series A investors. Joining the Mediar board from Amplitude Ventures is Bharat Srinivasa, PhD, and from ICG is Allan Marchington, PhD. Pro

Description: Following Oral Wegovy Introduction, Consumer Analysis Examines Injectable vs Oral Semaglutide Pricing, Compounded Tirzepatide Access Through Direct Meds, and Three-Entity Telehealth Platform StructureHOUSTON, TX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Medical decisions about prescription weight-management treatments are appropriately made with a qualified clinician who can evaluate individual risks and eligibility.

Description: Novo Nordisk's new GLP-1 pill highlights the risk that Eli Lilly faces, as investors reward it for being at the forefront of the weight loss market.

Description: Shares of Ventyx Biosciences launched late Tuesday on reports Eli Lilly could be nearing a $1 billion deal to buy the company.

Description: Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be acquired by Eli Lilly. A deal for Ventyx, which specializes in developing pills that can treat inflammatory diseases, could be announced imminently, the Journal reported, citing people familiar with the matter.

Description: Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.

Description: Health care stocks rose late Tuesday afternoon with the NYSE Health Care Index gaining 1.9% and the

Description: Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1 billion, according to people familiar with the matter. A deal for Ventyx, which specializes in developing pills that can treat inflammatory diseases, could be announced imminently, the people said. Ventyx, of San Diego, had a market value of a little over $500 million as of Tuesday afternoon.

Description: Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.

Description: Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Description: Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.

Description: IBD SwingTrader name Alphabet and IBD 50 watchlist stock Eli Lilly have made the IBD Screen Of The Day, which is focused on Stocks That Funds Are Buying. Google stock is nearing the buy point of a flat base, while Lilly shares pulled back Monday on competitor Novo Nordisk's breakthrough drug launch.

Description: Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.

Description: Eli Lilly offers investors safety and growth.

Description: BOSTON, January 06, 2026--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company ("Lilly") to develop a novel oral treatment for obesity and other metabolic diseases.

Description: Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.

Description: Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.

Description: Pagaya, Eli Lilly and Weatherford have been highlighted in this Investment Ideas article.

Description: Eli Lilly (LLY) is back in focus after recent trading put its market performance under the microscope, as investors weigh its current valuation against multiyear total returns and the company’s large pharmaceutical portfolio. See our latest analysis for Eli Lilly. At a share price of $1,080.36, Eli Lilly’s 30 day share price return of 6.93% and 90 day share price return of 28.06% sit alongside a 1 year total shareholder return of 42.26% and a very large 5 year total shareholder return. This...

Description: Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -3.6% change compared to its last close.

Description: ↗️ Trump Media (DJT): Shares in President Trump's social-media company rose 4.5% Monday. The U.S. ousted Venezuelan President Nicolás Maduro over the weekend and Trump pledged to dispatch U.S. drillers to revive Venezuela's crude output.

Description: Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index easing 0.1% and

Description: As GE Aerospace soars and Google stock sets up, a barrage of top names on the IBD Leaderboard come into focus.

Description: Novo Nordisk (NVO) said Monday that its Wegovy pill, the first oral medicine for obesity in the US,

Description: Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.

Description: Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight-loss drugs. But Lilly has a rival drug in the pipeline.

Description: Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.

Description: Novo Nordisk's New Wegovy Pill Tests the Limits of Demand

Description: Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.

Description: The company appears to have gotten the jump on Eli Lilly with what could be an important evolution in the market.

Description: LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.

Description: Novo Nordisk’s shares rallied after the drugmaker said its new Wegovy weight-loss pill is now broadly available in the U.S., following regulatory approval last month. The Wegovy product is the first GLP-1 pill approved specifically for weight loss. It will tap into what analysts expect will be substantial demand from consumers seeking an alternative to the injections that have dominated the anti-obesity market to date.

Description: According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Description: Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Description: As the AI trade becomes "fractured," 2026 could see other stocks finally outshine the "Magnificent Seven."

Description: Novo Nordisk’s Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.

Description: Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.

Description: Novo Nordisk is launching a weight-loss pill price war as it seeks to keep pace with arch-rival Eli Lilly in the market for GLP-1 drugs. The...

Description: In late 2025, FlyteHealth announced a new direct-to-employer pathway that pairs its outcomes-focused obesity care platform with select Eli Lilly obesity medications for self-insured organizations, aiming to tackle cost uncertainty and fragmented treatment. This integration of Lilly drugs into an AI-driven, clinically validated employer program could deepen access to obesity therapies while reshaping how large health buyers manage long-term cardiometabolic care. Next, we’ll examine how this...

Description: Visa, ExxonMobil, Oracle, and Netflix have multi-year compounding potential for patient investors.

Description: Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.

Description: Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.

Description: US equity markets are poised to get a boost from strong corporate earnings this year as spending con

Description: Alpha Wealth Funds, LLC, an investment management company, released its Q3 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund returned 4.96% in September, bringing the YTD returns to 21.37%. This compares to the benchmark, S&P 500 September return of 3.65% and the year-to-date return through September […]

Description: These two companies have very different risk-reward profiles.

Description: We recently published 10 Stocks on Jim Cramer’s Radar. Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer’s radar. Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) scored a major win earlier this month after it secured the Food and Drug Administration’s (FDA) approval for its weight loss pill. The approval made the Wegovy […]

Description: Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly’s lead in obesity and diabetes treatment should hold for years.

Description: Warren Buffett steps away as CEO of Berkshire Hathaway, leaving behind a stock near all-time highs and with a market capitalization of more than $1 trillion.

Description: The stock already looks unstoppable, and this move won't hurt its momentum.

Description: Drugmakers Brace for January Price Changes

Description: FDA approves Vanda's Nereus, developed with Eli Lilly, supported by three pivotal clinical trials.

Description: The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs.

Description: List prices to rise an average of 4% despite federal pressure to curb costs.

Description: The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points.

Description: Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.

Description: The stock market will enter the final day of 2025 near highs — and key support. Shopify, Eli Lilly have forged new buy points.

Description: Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market. Cheaper generic versions are expected to arrive as early as March next year, and the window to build […]

Description: Chinese Patients May See More Accessible Obesity Treatments After Pharma Price Moves

Description: AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.

Description: Lower costs aim to expand access in a fast-growing weight-loss market.

Description: <body><p>STORY: Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China.</p><p>Novo did not give details on the new prices.</p><p>But media outlet Yicai reported earlier that list prices for the two highest dosages of Wegovy were cut by 48% in some Chinese provinces.</p><p>The Danish drug maker confirmed a price adjustment to Reuters in a statement.</p><p>Lilly did not immediately respond to a request for comment.</p><p>According to a WeChat account for a hospital in the eastern city of Nanjing posted late last week, prices for Lilly's Mounjaro would also decrease from January 1st.</p><p>Over 65% of China's population of around 1.4 billion could be overweight or obese by 2030.</p><p>And both drugmakers are competing with rivals in the rapidly growing market.</p><p>They also face challenges after Novo's patent on Wegovy's active ingredient semaglutide expires in 2026 in China and other important markets.</p><p>Novo slashed Wegovy prices by up to 37% in India last month, as it seeks to gain ground in another fast-emerging market.</p><p>Both Novo and Eli Lilly also agreed to cut U.S. prices in November.</p></body>

Description: Joel F. Habener, a Harvard University academic whose research paved the way for revolutionary weight-loss drugs Ozempic, Mounjaro and others, which analysts forecast will be the biggest blockbusters in pharmaceutical history, died Sunday in Newton, Mass. He was 88. Eileen Martin, a friend of Habener’s, said he died peacefully at home. Habener led research that discovered a hormone dubbed GLP-1.

Description: Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.

Description: FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.

Description: Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now.

Description: Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again. Novo has a new weapon in its obesity portfolio with the once-daily Wegovy tablet, which is the first oral GLP-1 medication approved in the U.S. for weight loss. This comes at a time when ...

Description: Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts. These stocks provide rising income and often deliver superior total returns through compounding. Research from Hartford Funds, using Ned Davis Research data from 1973 to 2025, shows companies that grew or initiated dividends in the S&P 500 achieved higher ... Why Eli Lilly Is the Unexpected Must-Buy Dividend Powerhouse to Own in 2026

Description: Much in the new year depends on the fundamentals, which remain as complicated as ever. Watch these stocks.

Description: The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Description: If you're investing for the long run, there are a myriad of companies begging to be bought.

Description: These profitable businesses have plenty of room left to run.

Description: Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat

Description: Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H

Description: New research shows GLP-1 medications are changing food spending patterns well beyond weight loss

Description: US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.

Description: ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company ("Lilly").

Description: It's a two-horse race right now, sort of.

Description: As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

Description: Eli Lilly (LLY) and Novo Nordisk (NVO) are racing to cement their lead in India’s obesity drug market before cheaper generic version enter stores in March, Rishika Sadam of Reuters reports. Novo’s strategy focuses on price cuts and accelerated launches while Lilly’s products benefitted from entering the market early. Both companies have outreached to doctors, advertised heavily, provided incentives to patients, and entered distribution deals with local drugmakers, doctors, analysis, and others i

Description: In recent days, analyst Joseph Pantginis of H.C. Wainwright reaffirmed a positive stance on Viking Therapeutics after competitor Eli Lilly’s successful Phase 3 oral obesity study appeared to support Viking’s own oral obesity drug program. This external validation of Viking’s lead candidate VK2735 has sharpened investor focus on the company’s potential role in the rapidly evolving obesity treatment market. We’ll now examine how this strengthened confidence in VK2735’s commercial prospects...

Description: Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management fie

Description: <body><p>STORY: Packaged food makers and fast-food chains could be forced to overhaul more of their products next year as a newly-approved weight-loss pill hits the market.</p><p>That's according to food industry analysts who spoke to Reuters.</p><p>The U.S. Food and Drug Administration approved Novo Nordisk's Wegovy GLP-1 pill on Monday, sending shares of food companies down on Tuesday.</p><p>Eli Lilly's rival medication is expected to gain approval from regulators next year.</p><p>Up until now, GLP-1 medications have only been available in injectible form.</p><p>More Americans are expected to try the drugs as a pill rather than as a shot because the medication will be cheaper and many patients are hesitant to inject themselves.</p><p>Food companies including Conagra Brands and Nestle are already dealing with shifts in consumer tastes toward higher protein and smaller portions due to the popularity of weight-loss injections. </p><p>Earlier this year, Conagra started labeling some of its Healthy Choice frozen meals with high protein and fiber as, quote, "GLP-1 friendly." </p><p>Nestle, the world's biggest food company, has also introduced new frozen meals that cater specifically to GLP-1 users, called Vital Pursuit. </p><p>Some 40% of American adults are obese, U.S. government data shows, and around 12% of adults say they currently take GLP-1 drugs, according to a poll published last month by health policy research organization KFF.</p></body>

Description: NVO secures FDA approval for its first oral obesity pill, Wegovy, giving it a first-to-market edge and raising questions about Lilly's next move.

Description: Centennial, Colorado--(Newsfile Corp. - December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's recommendations and support for emerging federal policies expected to dramatically improve treatment access for millions of Americans living with obesity. The OMA commends the Centers for Medicare and Medicaid Services (CMS) and pharmaceutical partners,...

Description: As the S&P 500 closes at a record high, buoyed by stronger-than-expected economic growth and a tech stock rally, investors are keenly observing which sectors might lead the market next year. Amidst this optimistic environment, identifying undervalued stocks becomes crucial as they may offer potential opportunities for those looking to capitalize on market inefficiencies.

Description: Novo Nordisk’s (NVO) newly approved version of Wegovy is planned to go straight to U.S. self-pay channels in early January, Maggie Fick of Reuters reports. As part of the company’s deal with the Trump administration in November, Novo and Lilly (LLY) agreed to sell starter doses of their weight-loss pills for $149 a month to U.S. Medicare and Medicaid patients as well as cash-paying customers without insurance coverage. The pill will serve as a test case for the cash-paying consumer market.Claim

Description: Earlier this week, CRISPR Therapeutics reported encouraging early-stage clinical data for its allogeneic CD19 CAR T therapy, zugo-cel, in aggressive B-cell lymphoma and autoimmune diseases, and disclosed a new collaboration with Eli Lilly to test zugo-cel alongside pirtobrutinib. By pairing strong initial response rates and a favorable safety profile with Lilly’s kinase inhibitor, CRISPR Therapeutics is broadening zugo-cel’s potential role across both oncology and autoimmune...

Description: Engaging one of the world’s most repressive regimes, Trump envoy bonded with Belarusian dictator over Zepbound and obtained the release of hundreds of prisoners.

Description: 0549 ET – Novo Nordisk should benefit from U.S. approval of a pill version of Wegovy, AJ Bell’s Russ Mould writes in a note. U.S. regulators approved the first GLP-1 weight-loss pill, a tablet formulation of Novo Nordisk’s Ozempic and Wegovy. The decision gives the Danish drugmaker an early advantage in the race to bring an oral obesity treatment to market, he says.

Description: On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare.

Description: Novo Nordisk surges after U.S. regulators approve the first GLP-1 pill, while shares of rival pharma giant Eli Lilly decline.

Description: Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss pill in the U.S. Novo’s American depositary receipts were up 7.3% at $51.61 after the company announced late Monday that the U.S. Food and Drug Administration (FDA) approved a pill version of Wegovy—the weight-loss version of the Danish company’s groundbreaking Ozempic drug and a competitor to Eli Lilly’s Zepbound. Novo said it expects to launch the Wegovy pill in the U.S. in early January.

Description: The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped.

Description: Yesterday, the Food and Drug Administration (FDA) approved Novo Nordisk‘s (NYSE:NVO) Wegovy weight-loss pill, the first of its kind. This once-daily tablet uses the same active ingredient — semaglutide — as the injectable Wegovy and Ozempic, but in a higher 25 mg dose to achieve comparable efficacy despite lower absorption because it is taken orally. ... Novo Nordisk Strikes First With Oral Wegovy — But Can It Outrun Lilly’s Looming Pill?

Description: Novo Nordisk’s FDA-approved Wegovy pill set to land on US shelves in January.

Description: Competition from Eli Lilly, copycat drugs, and pricing pressure is reshaping Novo's outlook despite an upcoming oral Wegovy launch.

Description: NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.

Description: CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.

Description: Eli Lilly Faces Pressure as Novo's Daily Pill Hits the Market;'

Description: Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights.

Description: NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.

Description: Yahoo Finance Executive Editor Brian Sozzi tracks some of Tuesday's trending tickers, including Novo Nordisk (NVO), Eli Lilly (LLY), D-Wave Quantum (QBTS), and Trump Media & Technology Group (DJT, DJTWW). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: US stock futures (ES=F, NQ=F, YM=F) are moving lower after the S&P 500 (^GSPC) closed higher on Monday, notching its third straight day of gains. Gold prices (GC=F) continue to climb to record highs this week, now ascending above $4,500 per ounce. The US Food and Drug Administration (FDA) has approved the first GLP-1 weight-loss pill from Novo Nordisk (NVO), with Eli Lilly (LLY) expected to soon reveal its own oral obesity drug. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.

Description: Shares rose 5% for Novo Nordisk as it looks to ease market pressures with a significant revenue stream.

Description: Approval gives Danish drugmaker early lead over Eli Lilly in obesity treatment race.

Description: The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight.

Description: Investors were excited about the possibility of a buyout with a high price tag.

Description: LLY's strong GLP-1 demand, international launches and new drug contributions highlight why it leads today's top analyst reports lineup.

Description: Health care stocks advanced late Monday afternoon with the NYSE Health Care Index rising 0.6% and th

Description: Health care stocks advanced Monday afternoon, with the NYSE Health Care Index up 0.5% and the State

Description: XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.

Description: We recently published 8 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock. Over the course of the year, the CNBC TV host has praised the firm’s lead in the weight loss drug industry […]

Description: FlyteHealth, a national leader in integrated cardio-kidney-metabolic care, today announced it will provide self-insured organizations with a new access pathway for obesity management medication from Eli Lilly and Company (Lilly) — supported by FlyteHealth's clinically rigorous, outcomes-driven care platform.

Description: Weight-Loss Drugs Face a 2026 Inflection Point. Here's What Changes Next

Description: The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad

Description: Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy in 2026. On December 15, Bank of America analyst Jason Gerberry lowered the firm’s price target on Eli Lilly to $1,268 from $1,286 with a Buy rating on the shares. BofA remains bullish on Eli Lilly’s stock due to the company’s […]

Description: Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 from $951 while reiterating a Buy rating on the stock. On December 12, Eli Lilly and Company provided updated data […]

Description: -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmun

Description: Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. Pantginis maintains […]

Description: Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company.

Description: Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.

Description: The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.

Description: Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and Company (NYSE:LLY) released updated results from Phase 3 EMBER-3 study of Inluriyo (imlunestrant), which is an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor […]

Description: Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly the problem Eli Lilly (LLY) seems to have cracked with its weight-loss pill. In a late-stage trial, patients switching from weekly injections to Lilly’s oral drug were able to maintain ...

Description: The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medications. Amid growing demand for such treatments, significant advancements in drug development are increasingly focused on long-term sustainability and safety to meet the needs of individuals struggling with weight maintenance. Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the ATTAI

Description: Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

Description: If you are wondering whether Eli Lilly is still worth buying after its huge run, you are not alone, and this article is going to unpack what the current price is really implying. The stock just closed at $1,056.88, adding 2.9% over the last week and 35.8% year to date, while compounding an eye catching 568.2% over five years. Investors have been digesting a steady flow of developments around Eli Lilly's obesity and diabetes drug portfolio, alongside growing expectations for its pipeline in...

Description: The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance coverage. That should change both health outcomes and the way Americas buy and consume food.

Description: Exploring the Fund's Recent Portfolio Adjustments

Description: The Trump administration has talked tough on drug prices, but the impact of its deals with drugmakers so far has been limited.

Description: Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Description: Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue growth in the midst of intense demand for obesity therapies. In a head-to-head Phase 3 trial, Zepbound demonstrated superior efficacy, with patients achieving 20.2% average weight ... Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Description: Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.

Description: NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.

Description: Futures signal the stock market may test key resistance again after Thursday's Micron-inflation gains. Oracle, FedEx, Nike are early movers.

Description: Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Description: Elanco Animal Health stock is having a great year—and Chief Executive Jeffrey Simmons is champing at the bit. Simmons spent $478,500 to buy 22,000 shares of the stock on Dec. 11 for an average price of $21.75, according to a Form 4 filed with the Securities and Exchange Commission. The purchase was made by a revocable trust and brings his total indirect ownership to 167,000 shares.

Description: Dow Jones futures were little changed overnight, along with S&P 500 futures and Nasdaq futures. FedEx and Nike reported after the close. The stock market rallied Thursday on a surprisingly tame CPI inflation report and strong Micron Technology earnings and blowout guidance.

Description: These industry titans have gone in opposite directions this year; is that likely to change?

Description: Eli Lilly and Company (NYSE:LLY) is included among the 12 Best Long Term US Stocks to Buy Now. On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 price target on the stock. That move followed a similar call from Goldman Sachs earlier. On December […]

Description: The latest trading day saw Eli Lilly (LLY) settling at $1, representing a +1.45% change from its previous close.

Description: Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.

Description: Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Stree

Description: FDA filing advances orforglipron as a needle-free GLP-1 alternative.

Description: We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $36.15 as of December 15th. Viking Therapeutics is a clinical-stage biotechnology company focused on metabolic and endocrine disorders, with its […]

Description: Although the injectable forms of the popular GLP-1 drugs are more effective, the pills under development are both easier to take and will be cheaper

Description: These two stocks have been going in opposite directions over the past few years.

Description: NEW YORK, December 18, 2025--The 43rd Barometer from Sermo, a fast, frictionless HCP social engagement platform and leader in healthcare insights, shows that pharma-led direct-to-patient (DTP) GLP-1 prescribing programs are transforming treatment access pathways. Yet findings from 953 surveyed GLP-1 prescribers reveal sharp divisions over how involved pharma should be in clinical evaluation and prescribing.

Description: Patients on the highly effective obesity treatments from Novo Nordisk and Eli Lilly face a dilemma after they lose weight on the drugs: Do you stay on the shots forever, or stop and risk gaining the weight back? Now, it looks like Eli Lilly has a solution. One idea, long discussed by Wall Street analysts, has been that Lilly and its peers could lock in long-term users with a pill for patients to switch to after shedding pounds on a shot like Lilly’s Zepbound or Novo Nordisk’s Wegovy.

Description: Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.2% in the morning session after the company released positive data from its Phase 3 "ATTAIN-MAINTAIN" trial, which evaluated the efficacy of its daily oral pill, orforglipron.

Description: J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

Description: AI and healthcare momentum remain strong heading into 2026. NVDA, AVGO and LLY stand out as high-growth leaders with earnings power still driving their rallies.

Description: NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.

Description: The company is running circles around its competition.

Description: Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to rece

Description: Eli Lilly and Company (LLY) will reduce the prices of its diabetes and weight-loss drugs Mounjaro an

Description: These two healthcare stocks have strong growth prospects, but they've been going in opposite directions.

Description: DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: <body><p>STORY: Coons noted that although regulatory changes have "weighed on some stocks within healthcare... we still like the weight-loss theme, particularly around Lilly."</p><p>The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Lilly's blockbuster drug Zepbound.</p><p>Lilly also produces Kisunla, a drug to slow Alzheimer's.</p><p>"When you're looking at Big Pharma, they're just way undervalued right now relative to the rest of the market," said Coons, who added, "we do like Merck as well."</p></body>

Description: The market is surging due to the rising prevalence of chronic diseases and a massive shift toward home-based self-administration. The rapid expansion of biologics necessitates advanced injectables, while smart, connected devices are enhancing patient adherence, fueling robust market growth globally.Chicago, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The global drug delivery devices market size was valued at US$ 212.6 billion in 2025 and is projected to reach US$ 450.7 billion by 2035, growing at a CAGR o

Description: Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at Duquesne Capital without a single losing year, but he does not own Nvidia (NASDAQ:NVDA), Palantir (NASDAQ:PLTR), and Eli Lilly (NYSE:LLY) today. We’ll look into why in a bit. Druckenmiller is a timeless icon who has ... Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly

Description: PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.

Description: NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of David Arthur as Chief Executive Officer.

Description: It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.

Description: MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance a next-generation therapeutic for obesity.

Description: Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.

Description: In December 2025, Amphastar Pharmaceuticals announced that the FDA approved its abbreviated new drug application for a teriparatide injection prefilled pen, deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with plans to launch the product in the US$585.0 million U.S. market by late 2025. A distinctive aspect of this approval is that Amphastar will manufacture the teriparatide product entirely in-house at its U.S. facility, which could reinforce supply reliability...

Description: Eli Lilly and Company (NYSE: LLY) will participate in the 44th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025. David A. Ricks, Lilly chair and CEO, will take part in a fireside chat on Tuesday Jan. 13 at 5:15 p.m., Eastern time.

Description: LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Description: MindMed and four other biotech disruptors face pivotal studies and FDA decisions in 2026, setting up high-risk, high-reward opportunities for bold investors

Description: Pre-Market Stock Futures: The futures are trading lower after what started as a bounce-back Monday turned into a reversal Monday, as the AI/Datacenter rotation trade continues to gather steam during the last whole trading week of 2025. Stocks rallied Monday on the open as traders tried to inject some holiday spirit, but by 12 noon ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More

Description: BOSTON, December 16, 2025--Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs.

Description: In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.

Description: Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as "historic" and "the beginning of the end" for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan's Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural editi

Description: Eli Lilly and Company (NYSE:LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on December 12, Scotiabank analyst Louise Chen reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) and set a price target of $1,165.00. In another development, Eli Lilly and Company (NYSE:LLY) announced on […]

Description: Health care stocks rose late Monday afternoon with the NYSE Health Care Index gaining 1.2% and the S

Description: Can anything stop this high-flying drugmaker?

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the State Stre

Description: Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the stock benefited as investors rotated capital out of the volatile technology sector and into defensive names.

Description: NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: (Updates with Novo Nordisk's response in the fifth paragraph.) Eli Lilly's (LLY) experimental we

Description: RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide ...

Description: Eli Lilly shares have climbed in the double digits this year.

Description: Bears mauled AI stocks, but the Dow Jones and Russell 2000 hit new highs last week. Tesla and Eli Lilly are in buy zones.

Description: Why Eli Lilly Stock Keeps Pushing Higher Eli Lilly (LLY) has been grinding higher again, with shares up roughly 2% over the past week and more than 30% this year, as investors lean into its diabetes and obesity franchise. See our latest analysis for Eli Lilly. With the share price now around $1,027.51 and a powerful 90 day share price return of about 36%, momentum looks firmly intact and echoes Eli Lilly’s multi year total shareholder return that has hugely rewarded patient holders. If Eli...

Description: These habitual market beaters can pull it off again.

Description: Bears mauled AI stocks, but the Dow Jones and Russell 2000 hit new highs last week. Tesla and Eli Lilly are in buy zones.

Description: Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks struggle.

Description: Micron and Nike are among the week's big earnings reports. But economic news may steal the show, as the flow of federal attempts to recover.

Description: Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Description: Bears mauled AI stocks, but the Dow Jones and Russell 2000 hit new highs last week. Tesla and Eli Lilly are in buy zones.

Description: On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young as 10.

Description: Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.2% and the S

Description: Health care stocks edged up in Friday afternoon trading, with the NYSE Health Care Index adding 0.2%

Description: Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in 2025.

Description: Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer (MBC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. As monotherapy, imlunestrant demonstrated a clinically meaningful 38% reduction in the

Description: LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.

Description: Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.

Description: The Dow Jones and Russell 2000 hit record highs this past week, buoyed by a Fed rate cut and dovish Fed Chief Powell. Broadcom and Oracle weighed on techs.

Description: Companies like Cigna and CVS are promising simpler prices, but the behind-the-scenes system remains complex.

Description: A Democratic proposal to extend enhanced ACA subsidies failed in the Senate. It’s just weeks to go until millions of Americans covered under the Affordable Care Act face soaring costs for their coverage when the subsidies lapse. The shift is a huge departure from how pharma companies have sold drugs for decades and threatens the multibillion-dollar business of firms that have traditionally filled prescriptions.

Description: <body><p>STORY: Novo Nordisk launched Ozempic in India on Friday (December 12).</p><p>The Danish drugmaker priced the weight-loss drug at just over $24 per week for a 0.25 mg dose.</p><p>Novo is targeting a booming diabetes and obesity market in the country.</p><p>India has the world’s second-largest population of type 2 diabetes patients after China, and rising obesity rates.</p><p>That has turned it into a key battleground for weight-loss drugs</p><p>Ozempic has become a global bestseller and is widely used for weight loss.</p><p>Novo has said the drug also lowers the risk of cardiovascular events and kidney issues.</p><p>Friday's update is a bright spot in a challenging year for Novo.</p><p>It has faced strong competition from U.S. rival Eli Lilly and seen its share price drop heavily.</p></body>

Description: Europe's former pharma king is in freefall as Eli Lilly tightens its grip and investors demand answers.

Description: The Dow Jones and Russell 2000 hit record highs while the Nasdaq slashed early losses. Broadcom sees AI chip sales doubling.

Description: AbbVie dips below its 50-day SMA, but strong immunology momentum and a resilient long-term trend keep the story compelling.

Description: Lilly is investigating retatrutide in seven other Phase III trials, which are due to read out in 2026.

Description: Eli Lilly's (LLY) experimental weight-loss pill orforglipron may receive US Food and Drug Administra

Description: The pharmaceutical stock can still deliver.

Description: The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

Description: The Dow Jones and Russell 2000 hit record highs while the Nasdaq slashed early losses. Broadcom sees AI chip sales doubling.

Description: Eli Lilly is putting the "obesity field on notice again," an analyst said Thursday after its next-gen delivered 28.7% weight loss.

Description: The Dow Jones Industrial Average jumped 646 points and topped its own record set last month. Weakness for AI-related stocks, though, weighed on the Nasdaq composite, which fell 0.3%. Gains for Eli Lilly, banks and smaller stocks helped offset a steep drop for Oracle, whose plans for increased spending on AI surprised analysts.

Description: Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 0.9% and the Sta

Description: Eli Lilly (LLY) said Thursday that a late-stage trial of retatrutide, its injectable weight-loss dru

Description: ↗️ Disney (DIS): The company is investing $1 billion in OpenAI and will license its characters for use in ChatGPT and videos. Shares gained 2.4%. The deal was unveiled after Disney accused Google of infringing its copyrights "on a massive scale,” highlighting its carrot-and-stick approach to AI.

Description: Health care stocks rose Thursday afternoon, with the NYSE Health Care Index and the State Street Hea

Description: Lilly Boosts Lead in Weight-Loss Race as New Drug Hits All Endpoints

Description: Retatrutide just delivered over 23% weight loss in trials, raising the stakes in the $100B obesity race.

Description: Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the morning session after the company announced highly positive Phase 3 trial results for its next-generation weight loss candidate, retatrutide.

Description: The Dow Jones Industrial Average was down, while the S&P 500 and Nasdaq Composite were also lower in

Description: The company said some patients had dropped out of the trial because they felt they were losing too much weight.

Description: RHHBY's giredestrant cuts the risk of invasive disease recurrence or death by 30% in phase III, fueling momentum for a next-generation endocrine therapy.

Description: LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in the development of their GLP-1 therapies.

Description: Wave Life Sciences' shares jump 183% as early INLIGHT data on weight-loss drug WVE-007 show notable visceral fat cuts and gains in lean mass.

Description: A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television.

Description: Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including the results of Eli Lilly's (LLY) latest obesity drug test, Coca-Cola (KO) named Henrique Braun as the next CEO after current chief executive James Quincey steps down from the role at the end of March 2026, and Gemini Space Station (GEMI) receiving approval to operate as a predictions market by the Commodity Futures Trading Commission (CFTC). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a late-stage trial.

Description: This article first appeared on GuruFocus. Eli Lilly (LLY, Financials) reported late-stage results showing its next-generation obesity drug retatrutide produced the strongest weight loss seen so far in a phase-three trial and reduced knee pain in patients with obesity and osteoarthritis. The highest dose led to 23.7% average weight loss at 68 weeks when including all participants and 28.7% among those who completed treatment.

Description: GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.

Description: Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next.

Description: Investing.com -- Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.

Description: Eli Lilly said it plans to invest more than $6 billion in a new facility in Alabama to produce its experimental weight-loss pill.

Description: Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company (NYSE:LLY) announced results from the Phase 3 BRUIN CLL-314 clinical trial that was evaluating Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients living with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were either […]

Description: Project aims to boost supply of next-generation obesity drugs as demand keeps climbing.

Description: Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.

Description: Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.

Description: Project expands U.S. production capacity as demand for weight-loss drugs grows

Description: The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint.

Description: US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including YP050

Description: In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.

Description: The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.

Description: Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines.

Description: US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness.EXTON, PA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In November, the FDA granted National Priority Vouchers, and thus expedited review, to Eli Lilly’s orforglipron and a high-dose formulation

Description: Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

Description: Agreement deepens company's push into fast-growing weight-loss market

Description: Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.

Description: Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable insights. Known for his high-energy delivery and colorful metaphors, Cramer blends deep market knowledge with an ability to distill complex financial trends into digestible advice. While he doesn’t exclusively focus on dividend stocks, his analysis often ... Cramer Loves These Dividend Stocks

Description: Blockbuster drugs are a major driver of the growth of healthcare stocks.

Description: Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.

Description: Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the "Offer") by Flying Tigers Acquisition Corporation ("Purchaser"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares ("Shares") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right

Description: MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).

Description: Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37];

Description: A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.

Description: Molson Coors Beverage Company (NYSE:TAP) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On November 21, Piper Sandler lowered its price target for the stock to $50 from $52, while keeping a Neutral rating. The firm said it was revising its price target, taking into account recent developments in […]

Description: With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.

Description: After experiencing incredible rallies during 2025, these two stocks could decide to "split it" in 2026.

Description: The Fed is expected to cut rates another quarter point on Wednesday. The question is what comes next.

Description: Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.

Description: Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema.

Description: The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the first quarter of 2026 of $1.73 per share on outstanding common stock.

Description: Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.

Description: Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.

Description: Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy rating on the stock. The firm updated its models for LLY based on prescription trends and […]

Description: Neuroblastoma, a rare cancer mainly affecting children, is witnessing advancements in treatments, notably through immunotherapy, which has improved survival rates. Key innovations like gene and CAR-T cell therapies are accelerated by substantial government and private investments, transforming market dynamics. However, high treatment costs pose a challenge, particularly in low-resource settings. Leaders like Novartis and Eli Lilly drive innovation, focusing on sustainable products. The market's

Description: With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.

Description: Shares of Structure Therapeutics surged Monday after the biotechnology company said an experimental pill helped people lose substantial weight in a mid-stage clinical trial. The trial results raised hopes for high sales in the booming obesity-drug market. Analysts said the efficacy could make Structure’s pill competitive with Eli Lilly’s orforglipron, which Lilly hopes to introduce next year.

Description: The board of directors of Eli Lilly and Company (NYSE: LLY) elected Carolyn R. Bertozzi, Ph.D., as a returning member, effective Dec. 8, 2025. She will serve on the board's Science and Technology and Ethics and Compliance committees.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott’s medical device segment ... Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump

Description: Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed, along with the tech battleground. A caller asked Cramer about an optimal entry point into the stock, and he replied: “I think that people now are getting antsy and thinking that it’s really breaking down. That’s probably when I want to start […]

Description: Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve or were BTK inhibitor-naïve. Pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compar

Description: In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care.

Description: This is no reason to panic.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]

Description: These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Description: Eli Lilly's stock price and market cap are poised to explode with the GLP-1 market.

Description: New buys by the best mutual funds show AI stocks still in demand as AppLovin, Google and Broadcom shine. But Nvidia, Palantir go AWOL.

Description: Eli Lilly, Alphabet are among leading stocks in the IBD 50 list of growth stocks. Taiwan Semiconductor and AppLovin are near buy points.

Description: Futures rose with the market nearing record highs. Netflix agreed to buy Warner Bros. Will regulators agree? Ulta Beauty led earnings late.

Description: Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.

Description: If you are wondering whether Eli Lilly is still worth buying after its massive run or if the best days are already priced in, you are not alone, and that is exactly what we are going to unpack here. The stock has pulled back around 8.1% over the last week, but it is still up 11.9% over the past month, 30.4% year to date, and 564.0% over five years, which says a lot about how the market views its long term growth story. Recently, the spotlight has stayed firmly on Eli Lilly thanks to ongoing...

Description: Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new year.

Description: Small caps nearly hit all-time highs as the major indexes paused. Eli Lilly is at a key level while Robinhood led new buys. Ulta Beauty led earnings late.

Description: We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.’s share was trading at $71.54 as of December 2nd. Novartis is acquiring Avidity RNA, a pre-Phase 3 biotech company, in a straightforward deal with no overlap between the two businesses. The […]

Description: Danaher stock had its Relative Strength (RS) Rating upgraded from 68 to 72 Thursday — a welcome improvement, but still shy of the 80 or higher score you prefer to see.   When To Sell Stocks To Lock In Profits And Minimize Losses IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score.

Description: Novo Nordisk's weight on GDP, jobs, and exports is reshaping Denmark's growth story despite layoffs and tariff headwinds.

Description: We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $1,075.47 as of November 28th. LLY’s trailing and forward P/E were 52.69 and 33.90, respectively according to Yahoo Finance. Eli Lilly […]

Description: Lilly trades above key SMAs as strong GLP-1 demand, new drugs and pipeline momentum drive shares.

Description: In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.

Description: ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.

Description: Walmart's market value closed above a $900 billion for the first time on Wednesday. The retailer’s stock rose 1.8%, making it the 12th U.S. company to surpass the milestone, according to Dow Jones Market Data.

Description: Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

Description: A key catalyst may be right around the corner.

Description: Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts

Description: Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.

Description: NEW YORK, December 03, 2025--Excelsior Sciences, a company developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery, today announced it has raised $95 million to accelerate its mission to reinvent the process of discovering and manufacturing small molecules.

Description: Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record. In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp. The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.

Description: They are capitalizing on their ability to innovate and rewarding loyal shareholders in the process.

Description: Eli Lilly & Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly & Company (NYSE:LLY) reached another milestone on November 21, becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse. The company’s stock has rallied more […]

Description: By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapies and creating value, positions ReAlta for disciplined growth and leadership in rare and inflammatory diseases,” said Kenji Cunnion, M.D., MPH, ReAlta’s co-founder, Chief […]

Description: Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.

Description: After a rough pullback, the major indices are attempting to rebound higher. Helping, not only is Bitcoin starting to rebound, but so are down but not out tech stocks. Plus, markets are optimistic that the Federal Reserve will cut interest rates again next week. We also continue to see a significant number of upgrades from ... Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple

Description: November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.

Description: Janux’s “masked” T cell engager had a lower response rate than reported last year. Elsewhere, Lilly dropped Zepbound’s price and ACIP named a new chairman days before a key vaccine meeting.

Description: Key market opportunities for abemaciclib include growing demand for targeted therapies in oncology, advancements in combination therapies with immuno-oncology, and integration of personalized medicine. Emerging markets in Asia-Pacific, expanded cancer treatment access, and innovations in therapy delivery methods further bolster growth. Abemaciclib Market Abemaciclib Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets.c

Description: Eli Lilly and Company (NYSE:LLY) is one of the best dividend stocks to buy according to hedge funds. On November 23, Morgan Stanley analyst Terence Flynn maintained a Buy call on Eli Lilly, along with a price target of $1,290. In a different corporate update, dated November 24, Eli Lilly reported that it will present […]

Description: Eli Lilly recently became the 11th stock with a trillion-dollar valuation. S&P 500 titans Nvidia and Apple lead, but Google is rising fast.

Description: As the Nasdaq holds tough after a five-day win streak, Google stock, Robinhood and others land on list of stocks to watch.

Description: Eli Lilly said Monday that it's reducing the price of its popular weight-loss drug Zepbound on its LillyDirect platform, about a month after striking a deal with the Trump administration to lower drug costs.

Description: The company lowered monthly out-of-pocket costs as access initiatives expand.

Description: The move marks a victory for the Trump administration’s campaign to get other countries to pay more for drugs.

Description: Some professions — think tenured professor or Supreme Court justice — are largely insulated from the pressure to maintain a specific look. The same cannot be said in the high-stakes arenas of finance, real estate and design, where the quest for a competitive edge has well-established self-maintenance rituals: coloring gray hairs, meticulously curated wardrobe and submitting oneself to Botox needles. Now, that pursuit has evolved to include another new, potent class of injectable: glucagon-like p

Description: Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

Description: Eli Lilly is cutting prices again for those who pay cash for introductory doses of the weight-loss drug Zepbound. The lowest dose vial will cost $299 a month, that would be a saving of about $50. It's part of the price war with rival Novo Nordisk. Bloomberg's Madison Muller reports.

Description: The announcement came just weeks after rival Novo Nordisk cut prices for cash buyers of its top-selling weight loss drugs Ozempic and Wegovy

Description: Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.

Description: Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's LillyDirect website.

Description: Kalshi and Polymarket may not be a threat for much longer, as the gambling company gears up to launch its own prediction market.

Description: A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?

Description: Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a LiquidationREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by E

Description: The Morning Bull - US Market Morning Update Monday, Dec, 1 2025 US stock futures are drifting lower this morning as investors digest two big drivers: rising expectations of a Federal Reserve interest rate cut and a fresh jump in Treasury yields. The yield on the 10-year US government bond climbed to 4.04%, which signals that borrowing money is still expensive for both consumers and businesses. At the same time, market chatter points to a likely rate cut as soon as next week, which could make...

Description: New pill versions of weight loss drugs, lower prices, and patent expirations will all drive GLP-1 demand in 2026

Description: Eli Lilly’s stock has recently seen its consensus analyst price target rise from $1,003 to $1,024. This change reflects growing optimism among investors and follows fresh analyst reports and updated financial models, which are influenced by new product launches and expanding drug coverage. Stay tuned to discover how you can track these evolving perspectives and remain informed about future changes in Eli Lilly’s investment narrative. Stay updated as the Fair Value for Eli Lilly shifts by...

Description: This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon?

Description: Out of nowhere, on a holiday week no less, it seemed the stock market got a bid. The result was weekly gains for all the major averages. The Standard & Poor's 500 ended about 1% below its 52-week high, and Eli Lilly ended the week still sporting a market capitalization of $1 trillion. In the ...

Description: If you buy companies with in-demand products and hold for the long term, you can end up with long-term winners.

Description: Novo Nordisk's drug trial failure is the latest in a series of 2025 woes for the company.

Description: Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.

Description: These top growth stocks are worth a second look.

Description: Eli Lilly (LLY) just crossed a $1 trillion market cap, capturing attention on Wall Street as diabetes and weight-loss drugs continue to propel the company’s value. Demand for its GLP-1 therapies, such as Zepbound and Mounjaro, has surged, due in part to strong clinical trial results and wider coverage from Medicare and Medicaid. See our latest analysis for Eli Lilly. Shares in Eli Lilly have soared over the past year, with momentum building thanks to breakthrough obesity and diabetes drug...

Description: Mizuho Americas healthcare equity strategist, Jared Holz, joins Market Catalysts host Julie Hyman to discuss Eli Lilly's (LLY) stock action, how the GLP-1 market has played a part, and whether Eli Lilly will see serious competition in the oral GLP-1 market moving forward. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: The possibility of adding a new Big Tech customer helped lift an American chipmaker's stock on Friday, Nov. 28, 2025, while a recently hot pharmaceutical stock cooled.

Description: Shares of U.S. chipmaker Intel were leading the S&P higher as stocks edged upward on a holiday-shortened Black Friday session expected to be light on trading volume and corporate news.

Description: Lithium miner Albemarle came out on top, while Super Micro Computer led the list of worst performers.

Description: Michelle Carnahan has spent the better part of the last three decades working in healthcare at companies like Thirty Madison and Eli Lilly (NYSE:LLY). Now, the entrepreneur has raised $52 million in seed money for her own startup, Arbiter, a platform that connects health care professionals and payers to provide better patient care. The money has all been raised from family offices, including TriEdge Investments, MFO Ventures, and WindRose Health Investors, according to the company's funding anno

Description: Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Description: Lilly have been highlighted in this Investment Ideas article.

Description: PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.

Description: NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.

Description: As Eli Lilly makes history by joining the $1 trillion club, here’s how you can position for its next move.

Description: It's not only tech companies that can get to that market valuation.

Description: Eli Lilly recently became the first healthcare company to surpass a $1 trillion market capitalization, propelled by surging demand for its GLP-1-based diabetes and obesity drugs, Zepbound and Mounjaro, alongside significant pipeline developments and expanded Medicare and Medicaid coverage. This milestone reflects growing investor optimism about Eli Lilly's innovation pipeline, its manufacturing investments, and the potential for its upcoming oral obesity treatment to further transform the...

Description: Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.

Description: Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.

Description: ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.

Description: The stock recently reached beyond $1,000.

Description: GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.

Description: Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

Description: We recently published 11 Stocks Jim Cramer Shared His Insights On. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the pharmaceutical space. He has remained optimistic about the firm throughout the year and praised its lead in the weight […]

Description: U.S. government move slashes costs for key diabetes and weight-loss drugs beginning in 2027.

Description: The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.

Description: The weight loss drug market may approach almost $100 billion by the end of the decade.

Description: Eli Lilly and Company (NYSE:LLY) is included among the 15 Best Stocks to Buy for Medium Term. On‍ November 18, JPMorgan analyst Chris Scho‍tt r‌aised the firm‍’s‍ price ta‌rg​et on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 wh‍ile maintaining an Overw‍eig​ht ratin⁠g after meetings with management. JPMorgan said the di‌scu‌ss⁠ions‌ re‌inforced its positive […]

Description: The US government has negotiated a 71 per cent discount for Novo Nordisk’s weight-loss drugs Ozempic and Wegovy for patients enrolled in Medicare...

Description: Good news from a GLP-1 receptor agonist clinical trial hit the market today.

Description: A promising next-gen diabetes treatment just gave Novo Nordisk its first real jolt of hope in months.

Description: Bernstein just threw fresh fuel on Eli Lilly's (LLY) never-ending rally, as the firm lifted its price target on the stock to $1,300 from $1,100. For perspective, that’s an 18% bump compared to the old target, while representing a 21% to 22% upside compared to Lilly’s current stock price. ...

Description: Shares, though, were punished Monday after the drug maker said its blockbuster obesity treatment Wegovy failed to slow Alzheimer’s.

Description: The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.

Description: We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying. Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, […]

Description: IYH hits a 52-week high as healthcare gains momentum, lifted by sector strength and rising investor interest in safety and AI-driven tailwinds.

Description: J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.

Description: As the U.S. stock market kicks off a holiday-shortened trading week with significant gains, investors are buoyed by optimism around a potential Federal Reserve interest rate cut in December. In this environment of heightened confidence, identifying stocks that may be undervalued compared to their estimated worth can be particularly appealing, as they offer opportunities for growth amidst broader market enthusiasm.

Description: Eli Lilly’s remarkable outperformance within the pharmaceutical sector hasn’t tempered enthusiasm, analysts are still strongly bullish on its long-term growth potential.

Description: LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.

Description: As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

Description: Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies.

Description: Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12 in San Antonio, Texas. These updates reflect Lilly's continued progress across key pathways in hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer, the most common form of breast cancer.1

Description: The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s progression.

Description: Health care stocks rose late Monday afternoon, with the NYSE Health Care Index adding 0.3% and the H

Description: Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo Nordisk stock recently stood about 5.7% lower. The shares have tumbled by nearly three-quarters since hitting a peak at 1,028 Danish kroner in June last year.

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.5% and the Health Car

Description: The rapidly expanding market for GLP-1 drugs has added massively to Eli Lilly's market cap.

Description: President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.

Description: Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place Dec. 6-9 in Orlando, Florida.

Description: Fuelled by weight loss drug sales, Eli Lilly achieves a feat no healthcare company has before.

Description: A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.

Description: Eli Lilly (LLY) is benefiting from the "broadening" GLP-1 market for obesity and type-2 diabetes, Mo

Description: A pill with the key ingredient in Ozempic and Wegovy didn’t slow Alzheimer’s disease in two late-stage clinical trials.

Description: Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.

Description: LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.

Description: The selloff in European defense stocks (BA.L, RHM.DE, HO.PA, BAB.L) deepens as hopes grow around a peace deal draft for Ukraine and Russia. China's robotaxi firm WeRide (WRD) rallies on a massive revenue jump - even though the firm is still burning cash. In pharma, after Eli Lilly (LLY) hit $1 trillion: Bayer (BAYN.DE) stock flies, Novo Nordisk (NVO, NOVO-B.CO) tanks. For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.

Description: Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.

Description: The stock market needs to show a lot of strength after damaging recent losses. Watch Nvidia, Apple and Eli Lilly.

Description: These Magnificent Seven players are well-positioned to benefit in the AI boom.

Description: Who says you have to choose between the two?

Description: The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.

Description: The stock market rebounded Friday on Fed rate cut hopes but suffered damaging weekly losses. Nvidia, Apple and Eli Lilly are in focus.

Description: Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon.

Description: Curious whether Eli Lilly’s stock is still a smart buy after its rapid rise? Let’s break down the numbers and see if the current price matches up with real value. Shares have vaulted higher lately, climbing 30.5% in just the last month and notching a stunning 40.2% gain over the past year. Investors are watching Eli Lilly closely after headline-making developments in its obesity and diabetes drug pipeline sent the stock to new highs. This reflects excitement over blockbuster potential and...

Description: The market has been swinging recently, with the S&P 500 index down 1.5% and the Nasdaq Composite down more than 2% over the past month. Investors are now questioning whether the tech momentum can continue. Some non-tech stocks have performed well, and Eli Lilly (LLY) is one of them. Eli ...

Description: A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves

Description: Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.

Description: <body><p>STORY: Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progress of Alzheimer's disease.</p><p>Two trials have been described by Novo as a "lottery ticket".</p><p>They're testing its older diabetes pill that has the same active ingredient as Ozempic and Wegovy in thousands of people with mild Alzheimer's.</p><p>The goal is to decrease patients' rate of cognitive decline by at least 20%.</p><p>Alzheimer's experts say success would usher in a convenient new treatment to slow progression in a condition that affects 50 million people globally.</p><p>Researchers expect to glean important clues for future study into how and why these types of drugs, which include Eli Lilly’s Zepbound and Mounjaro, may be useful against the disease.</p><p>There are currently two drugs approved for slowing Alzheimer's by removing amyloid from the brain.</p><p>They are Lilly's Kisunla,  Leqembi from Eisai, and Biogen.</p><p>They were shown in clinical trials to slow disease progression by close to 30%.</p><p>Although they also carry the risk of serious side effects and require regular scans.</p><p>Novo is slated to present its results on December 3rd, although it could announce some data before then.</p></body>

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For

Description: Novo Nordisk just addressed a problem that has prevented some from taking these drugs.

Description: PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos Paya as Non-Executive Director. Carlos has a distinguished track record of leadership spanning academic medicine and the biopharmaceutical industry, with deep expertise in drug development and commercial strategy across early-stage start-ups to large-cap pharmaceutical companies.

Description: There are many ways to steer the ship as the top exec of a large pharma company. Here are the ones employees approve of the most — as well as those who could polish their image a little more.

Description: Viking Therapeutics stock fell Wednesday after the company said it overenrolled one of its final-phase studies for its weight-loss shot.

Description: Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Description: FEATURE Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods. The appeal of this group is its variety.

Description: Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new all-time highs. Shares are up 43% over the past year. Analyst sentiment is overwhelmingly positive, with most major firms rating LLY...

Description: The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for targeted therapies. Key innovations like immunotherapies, precision medicine, and early detection biomarkers are reshaping the market landscape, improving patient outcomes, and driving therapy adoption. Developed and emerging markets see enhanced care accessibility, propelled by investments in cancer i

Description: T. Rowe Price, a global investment management firm and a leader in retirement, announced the latest episode of "The Angle," an investment-themed podcast focused on timely topics shaping financial markets and featuring executives from some of the world's leading companies.

Description: Don't wait for a stock split to buy the stock, though.

Description: Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati

Description: ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.

Description: ​Novo Nordisk A/S (NYSE:NVO) is one of the Most Profitable Stocks to Buy Now. On November 17, Reuters reported that Novo Nordisk A/S (NYSE:NVO) will lower the US prices of its injectable Wegovy obesity drug. The price reduction for injectable Wegovy follows the company’s earlier announcement on November 6, where it agreed with the US […]

Description: Breakthrough Properties today announced that it has partnered with Eli Lilly and Company (Lilly) to launch Lilly Gateway Labs at Breakthrough at 2300 Market Street in Philadelphia. This new partnership provides innovative biotech companies comprehensive access to move-in ready labs, fully-equipped workspaces, and amenities they need to succeed and grow.

Description: Eli Lilly and Company (NYSE: LLY) today announced plans to open a new Lilly Gateway Labs (LGL) site in Philadelphia, bringing its distinctive model of scientific partnership to a city known for shaping the future of medicine.

Description: Eli Lilly and Company (LLY) shares up 15,892% since Big Money bought big in 1990.

Description: These stocks both have advanced in the double-digits in recent months.

Description: Microsoft posts strong cloud-fueled Q1 results as Azure surges and AI momentum builds, even as capacity limits pose near-term revenue constraints.

Description: Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed at a record, $973.8 billion, as Lilly inched closer to the $1 trillion market cap milestone.

Description: Microsoft shines in Zacks' top picks as strong cloud and AI momentum drive standout quarterly results and reinforce long-term growth potential.

Description: Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Description: Launch coming soon as India waits on final pricing plans

Description: Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.

Description: PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.

Description: Eli Lilly and Company (NYSE:LLY) will participate in the Citi's 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern time.

Description: We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer discussed. As he discussed Amgen, it was unsurprising that weight loss drug giant Eli Lilly and Company (NYSE:LLY) also caught Cramer’s attention. Throughout 2025, the CNBC TV host […]

Description: Crypto caught in broad market selloff, food, restaurant companies feeling relief, U.S.-China trade deal is fragile, and more news to start your day.

Description: Eli Lilly might soon join them for a far different reason: the weight-loss bonanza. This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker Novo Nordisk That is why investors shouldn’t assume the rally stops at a trillion. Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.

Description: Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen reiterated its Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $960. This update came after the company announced an agreement with the US government to expand access […]

Description: Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.

Description: Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer expressed his thoughts on. A caller asked, as a long-time holder of substantial NVO shares that have significantly declined in value, if it is too late to exit the position. In response, Mad Money’s host said: “You gotta, okay, you gotta let it come […]

Description: Novo Nordisk undercut Eli Lilly and the Trump administration on Monday, slashing the cash price of its Wegovy and Ozempic.

Description: This cancer treatment stock is nearing a buy point of a base after quarterly earnings. The Eli Lilly partner reports positive trial news.

Description: Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.